A Randomised, Open-label, Multi-centre, 2-stage, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC) in Comparison With LDAC Alone in Patients Aged ≥ 60 With Newly Diagnosed Acute Myeloid Leukaemia (AML)

Inclusion Criteria:

- Provision of written informed consent

- Newly diagnosed male or female patients aged 60 and over

- De Novo or Secondary AML

- Not eligible for intensive induction with anthracycline-based combination
chemotherapy as a result of at least one of the following:Age ≥75 years; Adverse
cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance
status >2; Organ dysfunction arising from significant co-morbidities not directly
linked to leukaemia

Exclusion Criteria:

- Participation in another clinical study in which an investigational product was
received within 14 days before the first dose in this study, or at any time if the
patient has not recovered from side-effects associated with that investigational
product

- Administration of LDAC is clinically contraindicated

- Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)

- Patients with blast crisis of chronic myeloid leukaemia